Tags

Type your tag names separated by a space and hit enter

Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Public Health Nutr. 2007 Oct; 10(10A):1200-5.PH

Abstract

BACKGROUND

Modification of lifestyle is the main therapeutical approach in the treatment of obesity, but use to fail on long terms of time. Addition of anti-obesity drugs allows keeping the weight loss during years and improving obesity-related comorbidities.

METHODS

This review is an actualisation on efficacy, safety and tolerability of the approved drugs on the long-term treatment of obesity (orlistat and sibutramine). New indications and effects of their use far beyond the weight loss are as well commented. Finally, potential benefits of the administration of CB1 antagonist rimonabant on the weight loss and cardiometabolic risk factors are analysed in detail.

DISCUSSION

A decade of experience on the use of orlistat and sibutramine has demonstrated their higher efficacy on the weight loss when compared to placebo either on adult or teenage population as well as safety and tolerability on long-term administration. Beneficial effects on the lipid profile, glycosilated haemoglobin on diabetic patients, blood pressure and levels of inflammatory cytokines, contribute to decrease the cardiovascular risk on obese patients. Phase III clinical trials using rimonabant show additional benefits to the expected weight loss, mainly reducing visceral fat and cardiometabolic risk factors.

CONCLUSION

Pharmacological treatment of obesity must be considered as a therapeutical tool that has to be used together with long-term lifestyle changes, contributing to the body weight reduction as well as to the improvement of the cardiometabolic risk related to obesity.

Authors+Show Affiliations

Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, c/ Martín Lagos s/n, 28040 Madrid, Spain. mrubio.hcsc@salud.madrid.orgNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17903331

Citation

Rubio, Miguel A., et al. "Drugs in the Treatment of Obesity: Sibutramine, Orlistat and Rimonabant." Public Health Nutrition, vol. 10, no. 10A, 2007, pp. 1200-5.
Rubio MA, Gargallo M, Isabel Millán A, et al. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public Health Nutr. 2007;10(10A):1200-5.
Rubio, M. A., Gargallo, M., Isabel Millán, A., & Moreno, B. (2007). Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public Health Nutrition, 10(10A), 1200-5.
Rubio MA, et al. Drugs in the Treatment of Obesity: Sibutramine, Orlistat and Rimonabant. Public Health Nutr. 2007;10(10A):1200-5. PubMed PMID: 17903331.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. AU - Rubio,Miguel A, AU - Gargallo,Manuel, AU - Isabel Millán,Ana, AU - Moreno,Basilio, PY - 2007/11/21/pubmed PY - 2008/2/2/medline PY - 2007/11/21/entrez SP - 1200 EP - 5 JF - Public health nutrition JO - Public Health Nutr VL - 10 IS - 10A N2 - BACKGROUND: Modification of lifestyle is the main therapeutical approach in the treatment of obesity, but use to fail on long terms of time. Addition of anti-obesity drugs allows keeping the weight loss during years and improving obesity-related comorbidities. METHODS: This review is an actualisation on efficacy, safety and tolerability of the approved drugs on the long-term treatment of obesity (orlistat and sibutramine). New indications and effects of their use far beyond the weight loss are as well commented. Finally, potential benefits of the administration of CB1 antagonist rimonabant on the weight loss and cardiometabolic risk factors are analysed in detail. DISCUSSION: A decade of experience on the use of orlistat and sibutramine has demonstrated their higher efficacy on the weight loss when compared to placebo either on adult or teenage population as well as safety and tolerability on long-term administration. Beneficial effects on the lipid profile, glycosilated haemoglobin on diabetic patients, blood pressure and levels of inflammatory cytokines, contribute to decrease the cardiovascular risk on obese patients. Phase III clinical trials using rimonabant show additional benefits to the expected weight loss, mainly reducing visceral fat and cardiometabolic risk factors. CONCLUSION: Pharmacological treatment of obesity must be considered as a therapeutical tool that has to be used together with long-term lifestyle changes, contributing to the body weight reduction as well as to the improvement of the cardiometabolic risk related to obesity. SN - 1368-9800 UR - https://www.unboundmedicine.com/medline/citation/17903331/Drugs_in_the_treatment_of_obesity:_sibutramine_orlistat_and_rimonabant_ L2 - https://www.cambridge.org/core/product/identifier/S1368980007000717/type/journal_article DB - PRIME DP - Unbound Medicine ER -